Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data: #ASH23

SAN DIEGO — Ar­cel­lx raised the cur­tain on the CAR-T da­ta it will present on Mon­day at the Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence as it read­ies a mul­ti­year plan to take on J&J and Leg­end Biotech’s Carvyk­ti, as well as Bris­tol My­ers Squibb’s Abec­ma.

Da­ta from a Phase I mul­ti­ple myelo­ma study for Ar­cel­lx’s an­i­to-cel, for­mer­ly known as CART-ddBC­MA, showed a 100% over­all re­sponse rate in 38 evalu­able pa­tients, in­clud­ing 29 (76%) with a com­plete re­sponse. Ad­di­tion­al­ly, in a group of 28 pa­tients evalu­able for min­i­mal resid­ual dis­ease (MRD) test­ing, me­di­an du­ra­tion of re­sponse, pro­gres­sion-free sur­vival and over­all sur­vival mea­sures have not yet been reached.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.